Gene Modified Tumor Infiltrating Lymphocytes(Chineo)

N/A

Report date: 2023/02/16 18:10:18

Base Information

Drug NameGene Modified Tumor Infiltrating Lymphocytes(Chineo)
Drug Alias NameScTIL Injection(Chineo)ScTIL210 Injection(Chineo)ScTIL210
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating LymphocytesCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsDigestive System NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Chineo Medical Technology Co LtdBeijing Cancer Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Oriental HospitalPeking University
Inactive CompaniesBeijing Cancer Hospital
Active IndicationsDigestive System NeoplasmsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A